Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

BRISBANE, Calif., May 25, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) will outline the company's corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26. InterMune will conduct a live webcast of the presentations beginning at 8:30 a.m. EDT.  

Dan Welch, chairman, CEO and president will open the meeting by discussing key elements of the Company's Vision for 2015 and the five Key Success Factors to realize this Vision:

  • The timely and successful launch of Esbriet in Europe
  • The successful completion of ASCEND and the successful launch of Esbriet in the U.S. in 1H 2014
  • The marketing of Esbriet in territories beyond the EU and U.S.
  • The successful implementation of an aggressive Esbriet Life Cycle Management Strategy
  • The successful implementation of a comprehensive internal and external program to establish an attractive and balanced pipeline

"We have a clear vision of where we expect to be in 2015, and an effective strategy to realize that vision," says Mr. Welch. "We believe our 'Vision 2015' is exciting and realistic and will be realized by successfully executing on the five Key Success Factors that will be detailed tomorrow."  

Esbriet in Europe

On February 28, 2011, the European Commission (EC) granted marketing authorization for Esbriet (pirfenidone) in adults for the treatment of mild to moderate IPF, a progressive and fatal lung disease. Esbriet is now authorized for marketing in all 27 EU member states, as well as in Norway and Iceland.

Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for EsbrietĀ® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Inc. (NASDAQ: VVUS ) today announced that ... review the company,s new drug application (NDA) for its investigational ... The target date for the FDA to complete its review ... announced results from the pivotal phase 3 trials, patients treated ...
... 2011 Kimberly-Clark Health Care (KCHC) announced today ... on synthetic exam gloves due to unprecedented demand ... butadiene and acrylonitrile.   "Despite aggressive ... along with inflationary pressures have been beyond expectations," ...
Cached Medicine Technology:VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 2VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction 3
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and ... with 30 years of practice experience in Dallas, Texas, ... benefits of dietary detoxification. The second study is scheduled ... results from test patients who just completed a 21-day ... interest in conducting the study, Dr. Casad said, "About ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... , , ... outdoor ground-level ozone, microscopic particle pollution like smoke and smog, ... is sensitive to these airborne contaminants to experience shortness of ... and cause lung irritation(1). According to AIRNow.gov(2), a government-developed index ...
... from Columbia University Medical Center,s Herbert Irving Comprehensive Cancer Center ... make new neurons but that may be hijacked later ... called Huwe1 normally functions to eliminate other unnecessary proteins and ... cancer. These findings, published in the August 18 ...
... biologist, a physicist, and a nanotechnologist walk into a ..." ... the start of a collaboration that has helped to decipher ... cells divide. Errors in cell division can cause mutations that ... the role of chromosome abnormalities in uncontrolled cell replication. ...
... an MP3 device -- just about every man, woman and child on ... of music, of the primal place it holds in the human imagination. ... of the soul -- a frill that has to go when school ... The study shows that musicians -- trained to hear sounds embedded in ...
... good for your health, extreme exercise may be physically ... heroin addicts went into withdrawal after running excessively in ... the hardest had the most severe withdrawal symptoms. ... if excessive exercise is addicting, then maybe, to feel ...
... , , , EDINA, Minn., Aug. ... pain for millions of children and adolescents. As students prepare for school, ... to shed light on backpack safety. , , ... backpack pain and injuries. , , Does the ...
Cached Medicine News:Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3Health News:Gene vital to brain's stem cells implicated in deadly brain cancer 2Health News:Gene vital to brain's stem cells implicated in deadly brain cancer 3Health News:Newly discovered mechanism in cell division has implications for chromosome's role in cancer 2Health News:Newly discovered mechanism in cell division has implications for chromosome's role in cancer 3Health News:Taking up music so you can hear 2Health News:Taking up music so you can hear 3Health News:Excessive exercise can be addicting, new study says 2Health News:It's Backpack Safety Time 2
... FSH Menopause Predictor Test is a ... detection of Follicle Stimulating Hormone (FSH) ... body hormone changes related to the ... menopause. The FHS Menopause Predictor ...
... pylori Rapid Test Strip and Device are ... of antibodies to Helicobacter pylori (H. pylori) ... aid in the diagnosis of H. pylori ... and older. They are intended for health ...
... Biotech Uni-Gold™ H. pylori assay is ... qualitative detection of IgG antibodies to ... human serum, plasma or whole blood ... of H. pylori infection in patients ...
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Medicine Products: